- The Wall Street Journal•10 hours ago
A trio of pharmaceutical companies is financing an effort by Aquinnah Pharmaceuticals Inc. to use a new approach to tackling neurological diseases that have long frustrated drugmakers.
- American City Business Journals•2 days ago
Juno Therapeutics Inc. has added Celgene Corp. President of Research and Early Development Dr. Rupert Vessey to the Seattle-based biotech's board. Vessey will serve as as Celgene's designated appointee to Juno's board, replacing Dr. Tom Daniel, who retired last summer but will remain on the board as an independent director. Juno (JUNO) inked a $1 billion collaboration with Celegene in 2015.
- TheStreet.com•3 days ago
The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.
CG3.BE: Summary for CELGENE CORP. DL-,01 - Yahoo Finance
CELGENE CORP. DL-,01 (CG3.BE)
Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
As of 8:08AM CEST. Market open.
People also watch
|Day's range||114.40 - 114.40|
|52-week range||109.75 - 118.68|
|PE ratio (TTM)||N/A|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|